Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trials 89.3% Effectiveness
Source: Streetwise Reports (1/29/21) Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial. Biotechnology company Novavax Inc. (NVAX:NASDAQ), which is focused on developing next-generation vaccines to address serious infectious diseases, yesterday announced that "NVX-CoV2373, its protein-based COVID-19 vaccine candidate, met the primary endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 ...
Source: streetwisereports.com